Further studies are needed to clarify the utility of the 5-HTT and 5-HT1A polymorphisms to optimize NIBS outcomes for patients with treatment-resistance depression, and existing studies suggest these polymorphisms may be potential genetic predictors of treatment efficacy. This evidence concerns the gene HTR1A and depressive disorder.